HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 275, Issue 47, 36509-36513, November 24, 2000

This Article Abstract Full Text (PDF) All Versions of this Article: 275/47/36509    most recent M005943200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giannoukakis, N. Articles by Robbins, P. D. Search for Related Content PubMed PubMed Citation Articles by Giannoukakis, N. Articles by Robbins, P. D. Social Bookmarking                      What's this?

Protection of Human Islets from the Effects of Interleukin-1 by Adenoviral Gene Transfer of an IB Repressor^*

Nick Giannoukakis^§, William A. Rudert^¶, Massimo Trucco^¶, and Paul D. Robbins

From the Departments of  Molecular Genetics and Biochemistry and of ^¶ Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261

Received for publication, July 6, 2000, and in revised form, August 23, 2000

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Interleukin-1 (IL-1) is a pro-inflammatory cytokine that inhibits  cell function and promotes Fas-triggered apoptosis. IL-1 is thought to act early in the initiation of the autoimmune destruction of pancreatic  cells in type I diabetes. IL-1 promotes  cell impairment, in part, by activating NF-B transcription factor-dependent signaling pathways. We have examined whether  cells could be protected from the effects of IL-1 by overexpressing an inhibitor of NF-B activity, IB, by adenoviral gene transfer to intact human islets in culture. Infection of islets with an adenoviral vector encoding a non-phosphorylatable, non-degradable variant of IB resulted in normal insulin responses to glucose in the presence of IL-1. Furthermore, nitric oxide production was prevented and, more importantly, Fas-triggered apoptosis was inhibited following IB gene transfer. These results suggest that blocking the NF-B pathway might prevent cytokine-induced  cell impairment as a means of facilitating islet transplantation.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The processes that lead to autoimmune diabetes mellitus include an as-yet-undefined trigger within islets that activates islet-resident, antigen-presenting cells to acquire antigens expressed by  cells. It is thought that antigen acquisition is consequent to  cell apoptosis. Once activated, the antigen-presenting cells are able to migrate to the peripheral lymphoid organs where they can activate autoreactive naïve T-lymphocytes that have escaped thymic or peripheral negative selection (1). Pro-inflammatory cytokines such as interleukin-1 (IL-1)¹ play important roles in this process (2).

IL-1 is released by macrophages in response to a variety of changes in a given tissue (3). The importance of IL-1 production by islet-resident macrophages in the onset of autoimmune diabetes has been suggested in several related studies. Depletion of macrophages in BB rats and in cyclophosphamide-treated non-obese diabetic (NOD) mice by silica particles has been shown to prevent diabetes (4, 5). In rodents, islet-resident macrophages are important for the initiation of  cell dysfunction and produce TNF, resulting in the induction of nitric oxide (NO) production by up-regulation of the inducible nitric oxide synthase enzyme (iNOS) (2, 3, 6-8). The inhibition of  cell function and the promotion of NO production is an IL-1-dependent process in rodents (6, 8, 9). Whether IL-1 is acting alone via NO in promoting  cell dysfunction and apoptosis activation in human islets is still unclear (10-12). Nitric oxide itself is toxic to  cells, because it is readily converted to peroxynitrite (13, 14). Islet-resident macrophages as well as  cells in the NOD mouse begin displaying an increase in iNOS protein at about 5 weeks of age coincident with the onset of insulitis (15). Finally, insulitis progression, defined cytologically as an increase in macrophage and T-lymphocyte infiltration in and around the islets of Langerhans, is associated with increasing levels of iNOS expression and protein in  cells of the NOD mouse (15, 16).

The promoters for a number of cytokine-sensitive genes, including iNOS, ICAM-1, Fas, and Fas ligand possess binding sites for members of the NF-B family of transcription factors (17-22). The regulation of NF-B activity has been implicated in  cell impairment. NF-B activity is increased in rat insulinoma cells (RIN) in culture in response to IL-1 (23), whereas cytokines were also shown to promote NF-B activity in human and rodent islets in vitro (24). Moreover, iNOS expression in RINm5F insulinoma cells is dependent on NF-B transactivation of the promoter in response to IL-1 (24). Additionally, this requirement for NF-B activation for iNOS expression was observed in human  cells as well as in rat islets in culture in response to IL-1 (24). Another gene that is activated in response to IL-1 and very likely involved in  cell dysfunction is cyclooxygenase 2 (COX-2), the enzyme that catalyzes the formation of the pro-inflammatory prostaglandin E₂. In human and hamster islets, COX-2 expression is induced in response to IL-1, and this is paralleled by an increase in NF-B-dependent activation of the COX-2 promoter (25). Furthermore, TNF-induced apoptosis in NIT-1 mouse insulinoma cells as well as primary islets is paralleled by an activation of NF-B (26).

NF-B activity is regulated by a group of naturally occurring repressors termed IB (27). IB is normally bound to NF-B, resulting in retention of the complex in the cytoplasm. Following inflammatory stimulation, such as exposure to certain cytokines like TNF and IL-1, IB is rapidly phosphorylated and targeted for ubiquitin-mediated degradation. The release of IB allows NF-B to translocate to the nucleus, where it binds its cognate enhancer elements upstream of pro-inflammatory genes (27, 28). IB has been shown to inhibit iNOS gene expression by associating with NF-B and preventing its translocation to the nucleus (29). Recently, a mutant version of IB has been engineered that is non-phosphorylatable and unable to be degraded (30). Expression of the mutant IB in cells from human arthritic joints, including macrophages, in vitro, suppressed TNF production (31). Adenoviral gene transfer of the mutant into human intestinal epithelial cells in vitro, blocked IL-1 and TNF-induced iNOS expression as well as IL-1 and IL-8 production (30).

In this report, we have examined the ability of a non-phosphorylatable, non-degradable variant of IBa, delivered by adenoviral gene transfer, to inhibit IL-1-mediated  cell destruction and apoptosis. We demonstrate that adenoviral gene transfer of the IB repressor to human islets in vitro can prevent IL-1-dependent suppression of glucose-stimulated insulin release and can inhibit nitric oxide production following exposure of the islets to IL-. Furthermore, we show that IL--mediated, Fas-triggered apoptosis induction can be prevented in islets by IB gene transfer. These results suggest that inhibition of the NF-B signaling pathway in islets may be one means of facilitating islet transplantation as a potential therapy for autoimmune diabetes.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Adenoviral Infection of Intact Human Islets in Vitro-- The IB repressor cDNA was used to generate an E1-deleted recombinant adenoviral vector, kindly provided by Dr. David Geller (University of Pittsburgh). The virus was propagated and purified as described (32). The E1/E3-deleted eGFP and LacZ adenoviral vectors were constructed by subcloning the cDNAs into the pAdLox shuttle plasmid followed by Cre-Lox recombination (33). In all instances, transgene expression was driven by the cytomegalovirus immediate-early promoter.

Pancreata from multiorgan cadaveric donors were provided by the National Disease Research Interchange (Philadelphia, PA) and local Organ Procurement Organizations with the appropriate consent for research use. Islets were obtained from the Diabetes Research Institute of the University of Miami (Dr. C. Ricordi) and from the University of Minnesota (Dr. Bernhard Hering). These sources participate in the Juvenile Diabetes Foundation International Islet Distribution Program. Pancreata were obtained from at least five cadaveric donors of different ages and sex and subjected to the digestion, isolation, and purification as described (34). The purity of islets was usually greater than 80% (mantled islets). Viability of the cultured islets was usually greater than 85% as assessed by vital dye exclusion, insulin staining, and morphology. The experiments described below used islets from the pancreata of five different donors.

Islets were washed twice in serum-free RPMI 1640 (Life Technologies, Inc.) prior to infection. 200-300 islets were infected with adenoviral vectors encoding IB (Ad-IB), -galactosidase (Ad-LacZ), or enhanced green fluorescence protein (Ad-eGFP) at 1 × 10⁶ plaque forming units (pfu) per 200-300 islets for 2 h at 37 °C. Following infection, islets were washed twice in serum-free medium and then cultured for 48 h in medium with 10% heat-inactivated fetal calf serum (Life Technologies, Inc.) containing a solution of 1% penicillin/streptomycin (Life Technologies, Inc.).

Glucose-stimulated Insulin Production and NO Output-- To determine the effects of IL-1 on  cell function of islets infected with Ad-IB or Ad-LacZ/Ad-eGFP as controls, glucose-stimulated insulin secretion was used as a functional assay. Islets were first treated with 50 units of recombinant human IL-1 (Sigma) for a period between 18 and 24 h immediately following a preincubation in fresh media between 16 and 24 h. The IL-1-containing medium was removed, and the islets were washed twice with Krebs-Ringer-HEPES buffer (KRH buffer; 25 mM HEPES, pH 7.4, 115 mM NaCl, 24 mM NaHCO₃, 5 mM KCl, 2.5 mM CaCl₂, 1 mM MgCl₂). Incubation was carried out at 37 °C in KRH buffer for 30 min followed by an additional incubation for 30 min in the presence of 5 and 18 mM glucose (final concentration). The buffer was subsequently removed, and its insulin content was determined by a commercially available enzyme-linked immunosorbent assay kit (Dako Chemicals), which specifically recognizes processed human insulin.

To evaluate NO production, the islet culture supernatants were collected between 18 and 24 h following the addition of IL-1, and an aliquot was subjected to the Griess reaction.

Determination of Apoptosis Activation in Vitro-- Uninfected islets, as well as those infected with Ad-eGFP as control or Ad-IB, were treated with 50 units of IL-1 for 24 h. Furthermore, a subset of islets untreated or pretreated with IL-1 were challenged with the agonistic human Fas antibody (clone CH-11, Upstate Biotechnology Inc.) for 1 h at 37 °C. Following incubation with antibody, islets were lysed and processed for the detection of caspase-3 (CPP32) activity using a commercially available kit (ApoAlert, CLONTECH, Palo Alto, CA). As an indirect means of correcting for cell number, the CPP32 activity was corrected by the number of nanograms of DNA in the lysate assayed, using the PicoGreen reagent, an intercalating DNA fluorogenic compound (Molecular Probes Inc.).

NF-B Reporter Gene Assay in Mouse Insulinoma Cells in Vitro-- To examine the effects of IB gene transfer on NF-B activity in vitro, subconfluent NIT-1 insulinoma cells (derived from the non-obese diabetic mouse; ATCC CRL-2055) were infected with Ad-IB at a multiplicity of infection of between 40 and 80 in serum-free RPMI 1640 for 1 h at 37 °C. The medium was then replaced with medium containing 10% fetal calf serum. After 24 h, the cells were transfected with a luciferase reporter gene fused to five tandemly arrayed NF-B consensus binding sites (Stratagene, La Jolla, CA) using the LipofectAMINE reagent as suggested by the manufacturer (Life Technologies, Inc., Gaithersburg, MD). 18-24 h later, the cells were treated with 50 units of IL-1. Uninfected, transfected cells treated with or without IL-1 were used as controls. All cells were lysed 24 h later for luciferase assay using a commercially available kit (Promega, Madison, WI).

Statistics-- Statistics were performed using the SPSS for Windows v. 8.0 package, and a p value of less than 0.05 by ANOVA was taken to indicate statistically significant differences.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Adenoviral IB Gene Transfer to Islets Prevents IL-1-induced  Cell Impairment and NO Production in Vitro-- Previous studies have demonstrated efficient adenoviral gene transfer to human and murine islets in culture with maintenance of normal  cell function as assessed by glucose-stimulated insulin release assays and glucose perifusions (35-37). In particular, we have demonstrated the ability to infect up to 70% of islet cells and 50% of the  cells with an adenoviral vector encoding the green fluorescence protein (38, 39). To determine if adenoviral gene transfer of the IB repressor was able to prevent the IL-1-induced impairment of glucose-stimulated insulin release by cultured human islets, we exposed uninfected islets as well as those infected with Ad-eGFP and Ad-IB to 50 units of recombinant IL-1. This amount, over a 24-h period, was sufficient to impair the ability of islets to respond to a high glucose challenge (18 mM) in all islet cultures examined (Fig. 1). However, the islets infected with Ad-IB responded similarly to uninfected control islets to increasing glucose (Fig. 1 and Table I). Why the level of insulin release at 5 mM of glucose is higher in Ad-IB-infected islets compared with the Ad-LacZ control is unclear. However, it is possible that there is low level activation of NF-B during the islet isolation procedure, which is inhibited by Ad-IB gene transfer.

View larger version (20K): [in this window] [in a new window]   Fig. 1.   Adenoviral gene transfer of IB to human islets prevents the IL-1-induced impairment of glucose-stimulated insulin release. 200-300 islets were infected with 1 × 106 pfu of Ad-LacZ or Ad-IB and exposed to 50 units of IL-1 for a period between 18 and 24 h. Uninfected islets served as control. Islets were then subjected to a static glucose-stimulated insulin release assay as described under "Experimental Procedures," and insulin was measured in the supernatant by enzyme-linked immunosorbent assay. The bars indicate the means of triplicate experiments with triplicate determinations each, and the error bars denote the S.E. The data are presented as percentage above control where the insulin secretion by untreated, uninfected islets exposed to 5 mM glucose is taken as 100%.

NO has been suggested to be the mediator of IL-1-induced suppression of insulin production in a number of instances in rodent islets (2, 6, 9, 40, 41); however, its role as a mediator in human islets is not fully clear (10-12, 42, 43). We determined the level of nitrite in the media of uninfected, Ad-LacZ-infected, and Ad-IB-infected islets in the presence or absence of 50 units of IL-1 by the Griess reaction. Nitrite accumulation was detectable in uninfected islets as well as Ad-LacZ-infected islets in the absence of IL-1. No significant accumulation above control values occurred when islets were infected with Ad-LacZ alone (Fig. 2). However, exposure of uninfected islets to IL-1 resulted in a significant accumulation (Fig. 2). The largest accumulation was seen in cultures infected by Ad-LacZ followed by IL-1 exposure (375 ± 40% versus control, p < 0.05, Fig. 2). This result is similar to previous observations demonstrating that adenoviral infection is able to partially increase the expression of NF-B-dependent genes like iNOS (44). However, gene transfer of IB was able to block both IL-1 and adenoviral-mediated induction of NO. More importantly, nitrite accumulation in the medium of Ad-IB-infected islets was no greater than control levels (100 ± 5% versus control, p = NS, Fig. 2).

View larger version (16K): [in this window] [in a new window]   Fig. 2.   Adenoviral gene transfer of IB to human islets can prevent IL-1-induced nitric oxide production. Groups of 200-300 islets were infected with 1 × 106 pfu of Ad-LacZ or Ad-IB and then exposed to 50 units of IL-1 for a period between 18 and 24 h. Uninfected islets served as control. The culture media were then collected and assayed for nitrite levels using the Griess reagent. Bars indicate the means of three different experiments each performed in triplicate, and the error bars denote the S.E. Values are shown as percentage of control where the nitrite level in mock infected, untreated islets is taken as 100%.

Ad-IB-infected Islets in Culture Are Protected from IL-1-induced, Fas-mediated Apoptosis Activation-- Cross-linking of the Fas antigen on a number of cell types using an IgM antibody has been shown to activate caspase-3 activity and apoptosis (45-48). For these experiments, we used Ad-eGFP as a control vector, because we have previously demonstrated that Ad-eGFP infection, like Ad-LacZ, of human islets in vitro does not affect their function or apoptosis activation (38, 39). Uninfected, Ad-eGFP-infected, and Ad-IB-infected islets were first exposed to 50 units of IL-1 for 18-24 h and then treated with the agonistic Fas antibody for 1 h. Caspase-3 activity was significantly suppressed in islets infected with Ad-IB compared with uninfected and Ad-eGFP-infected controls (Fig. 3). Ad-IB also was able to reduce apoptosis following IL-1 treatment but had no effect following the addition of Fas antibody. However, gene transfer of IB significantly suppressed the increase in apoptosis following treatment with IL-1 and subsequent treatment with the Fas antibody (Fig. 3). To rule out the possibility that the protection conferred to islets against Fas-triggered apoptosis activation was due to adenovirus-mediated down-regulation of Fas, islets were infected with a replication-defective herpes simplex-1 vector encoding IB (HSV-IB) or LacZ as control (HSV-LacZ). Following exposure of the islets to IL-1 and the agonistic Fas antibody, a decrease in caspase-3 activity was observed in islets infected with HSV-IB compared with the uninfected control (data not shown).

View larger version (26K): [in this window] [in a new window]   Fig. 3.   Infection of human islets in culture with an adenoviral vector expressing human IB can suppress IL-1-stimulated, Fas-triggered activation of apoptosis. 200-300 islets were infected with 1 × 106 pfu Ad-eGFP or Ad-IB and then treated with 50 units of IL-1 for a period between 18 and 24 h. Uninfected islets acted as control. Immediately thereafter, 250 ng of an agonistic anti-Fas antibody were added to each group, and the islets were lysed 1 h later. Caspase-3 activity was detected as described under "Experimental Procedures," and the value was corrected for cell number indirectly, by assessing the amount of DNA present in the lysate. The bars indicate the means of three independent experiments performed in triplicate, and the error bars denote the S.E. We show the means as percentage of control where the ratio of caspase-3 activity to DNA content in uninfected, untreated islets represents 100%.

Ad-IB Gene Transfer to Insulinoma Cells in Vitro Prevents IL-1-stimulated NF-B Activity-- To demonstrate that IB gene transfer inhibited NF-B activity, we performed transient transfection assays in Ad-IB-infected NIT-1 insulinoma cells with an NF-B-luciferase construct. In Fig. 4 we show that NF-B-luciferase reporter activity is significantly increased in uninfected cells treated with IL-1 (159 ± 10% versus control, p < 0.05). Ad-IB infection followed by transient transfection with the reporter resulted in reporter gene activity at levels lower than transfected control cells (57 ± 6% versus control, p < 0.05). More importantly, exposure of Ad-IB-infected, reporter gene-transfected cells to IL-1 did not lead to reporter gene activity at levels higher than those seen in uninfected, transfected control cells (65 ± 13% versus control, p < 0.05).

View larger version (12K): [in this window] [in a new window]   Fig. 4.   NF-B activity in Ad-IB-infected NIT-1 insulinoma cells in vitro. Infected cells were transiently transfected with an NF-B-luciferase reporter gene plasmid and subsequently treated with IL-1. Uninfected cells were used as controls. Results are shown as percentage of control, where luciferase activity in the lysates of uninfected, transfected cells was taken to be 100%. Experiments were performed twice in triplicate. The means are shown as columns with the error bars indicating the S.E.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Previous studies have demonstrated that adenoviral infection of intact human islets in culture does not change their viability or functional characteristics (36-39). Therefore, we have used adenoviral gene transfer to intact human islets in vitro to demonstrate that a human IB repressor can suppress IL-1-induced impairment of glucose-stimulated insulin secretion. There was no increase in nitrite accumulation in the media of Ad-IB-infected islets exposed to IL-1 compared with the increase seen in uninfected islet cultures treated with IL-1. This result is consistent with IB inhibiting NF-B activation, resulting in prevention of iNOS induction, an IL-1- and NF-B-sensitive gene (17, 24). Our transient transfection data in a  cell line suggest that Ad-IB gene transfer inhibits the effects of IL-1 by interfering with NF-B transcriptional activity. This inhibition is most likely due to direct interaction of IB with NF-B in the cytoplasm preventing NF-B translocation into the nucleus.

Ad-IB infection alone did not change the NO levels compared with uninfected, untreated islets. However, Ad-LacZ infection followed by IL-1 treatment, resulted in a dramatic increase in NO production that was paralleled by an increase in IL-1-induced, Fas-triggered apoptosis activation in Ad-eGFP-infected islets. The increased nitrite accumulation by Ad-LacZ-infected islets in the presence of IL-1 suggests that the adenoviral infection triggers intrinsic islet antiviral defense mechanisms that are perhaps mediated by resident macrophages and potentiated by exogenously added IL-1. Indeed, adenoviral infection has been shown to stimulate NO production (49, 50). In addition to endocrine cells, islets contain a small number of macrophages and dendritic cells that are likely targets of adenoviral infection. It is possible that the nitrite, detected in the Ad-LacZ-infected islets, was derived from islet-resident antigen-presenting cells that were activated in response to the viral proteins.

Although there is strong support for IL-1 alone inducing NO production and  cell dysfunction in rat islets, this does not always appear to be the case for human  cells (2, 8, 10-12, 51). Although it is unclear why there is such variability among the data among different investigators and experiments, some factors that could have influenced our findings can be ruled out, including: 1) the degree of islet contamination by non-endocrine, exocrine, or other pancreatic cells is minimal. We routinely used islet preparations of 80% or greater as assessed by microscopic morphology and insulin staining of intact islets and single cell cultures in addition to dithizone staining following a new and improved isolation protocol (34); 2) Variability of islet viability and function. We have used islets isolated from pancreata obtained from multiple donors of different ages and sex; and 3) Isolation-associated cell damage. The islets we have used have been isolated by a procedure that offers minimal cell trauma/damage (34). One important difference between our procedures and those in some other studies, where IL-1 alone could not promote NO production or  cell impairment, involves the culture conditions of the islets following isolation. It is possible that different culture conditions may promote  cell resistance to the effects of IL-1 by inducing the down-regulation (internalization) of the type I IL-1 receptor. Consequently, the relocation of the type I IL-1 receptor to the cell surface would require stimulation by cytokines like TNF or interferon .

Ad-IB infection was able to prevent the IL-1-induced, Fas-triggered activation of caspase-3 activity. It thus appears that NF-B activity is important for Fas-mediated apoptosis in  cells. Alternatively, NF-B activity could be required for expression of Fas. Basal caspase-3 activity in islets was also significantly reduced following Ad-IB infection, suggesting that NF-B is activated in islets during the isolation procedure. Thus, IB gene transfer could be useful to preserve islet function prior to, and following islet transplantation.

Apoptosis is a process involving the activity of caspases. To date, caspase-3 activation commits all cells examined, including  cells to apoptosis, and is an early step in mediating Fas signaling (52-56). In response to Fas ligation by the CH-11 monoclonal antibody, caspase-3 activation is seen as early as 5 min in a fibrosarcoma cell line (45). Although we have not formally ruled out the possibility that caspase-3 activity in our cultures partly derives from non- cells, that caspase-3 activity is at control levels in islets expressing IB demonstrates its utility to protect islet cells from the apoptotic Fas trigger.

NF-B is a transcriptional complex composed of homo- or heterodimers of proteins belonging to the Rel family of transcription factors. Activation of NF-B-dependent transcriptional processes usually occurs in response to inflammatory signals such as cytokines, however, it may also be associated with stress responses in a manner analogous to heat-shock proteins (57, 58). Although very little is known about non-inflammatory effects of NF-B-dependent gene expression as well as its targets in  cells under non-pathologic situations, this is an important area that requires further understanding to appropriately modulate repression of NF-B in gene transfer strategies. For example, levels of IB expression may have to be regulated to promote protection against pro-inflammatory cytokines, yet preserving normal NF-B responses to stress (57, 58). This could be achieved using gene transfer strategies using vectors with regulatable promoters like tetracycline or mifepristone (RU-486) (59-63). To prevent potential interference with normal cell function, other complementary strategies like cytokine blockade can be used. We have demonstrated such an approach by interfering with the effects of IL-1, an upstream activator of NF-B, using an adenoviral vector the interleukin-1 receptor antagonist protein in human islets in vitro (39).

In this report, we have demonstrated the feasibility of using an adenoviral vector encoding an IB repressor to infect human islets as a means of preventing IL-1-induced impairment of  cell function. Moreover, we have demonstrated that IB transduction of islets can suppress NO production in the presence of IL-1 as well as Fas-triggered caspase-3 activation, an early marker of apoptosis induction. We suggest that IB gene transfer to islets may be a means of preserving their integrity and promoting their survival and function prior to and following transplantation into diabetic hosts as a potential therapy for type I diabetes.

	ACKNOWLEDGEMENTS

We thank the Juvenile Diabetes Foundation International Islet Distribution Program; Elina Linetsky, Alessandra Ranuncoli (University of Miami), and Jeff Ansite (University of Minnesota) for the isolation and purification of human islets; and Christy Bruton and Bruce Baldwin for technical assistance.

	FOOTNOTES

^* This work was supported in part by a program project grant from the Juvenile Diabetes Foundation International (to M. T. and P. D. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ Recipient of a postdoctoral fellowship from the Juvenile Diabetes Foundation International and a prize from the Fonds pour la Formation de Chercheurs et a L'aide a la Recherche from the provincial government of Quebec, Canada.

To whom correspondence should be addressed: Dept. of Molecular Genetics and Biochemistry, W1246 BST, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261. Tel.: 412-648-9268; Fax: 412-383-8837; E-mail: probb@pitt.edu.

Published, JBC Papers in Press, August 30, 2000, DOI 10.1074/jbc.M005943200

	ABBREVIATIONS

The abbreviations used are: IL-1, interleukin-1; NOD, non-obese diabetic; TNF, tumor necrosis factor ; NO, nitric oxide; iNOS, inducible nitric oxide synthase; RIN, rat insulinoma; COX-2, cyclooxygenase-2; GFP, green fluorescence protein; pfu, plaque-forming units; HSV, herpes simplex-1 vector.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				T. Dai, M. Patel-Chamberlin, R. Natarajan, I. Todorov, J. Ma, J. LaPage, L. Phillips, C. C. Nast, D. Becerra, P. Chuang, et al. Heat Shock Protein 27 Overexpression Mitigates Cytokine-Induced Islet Apoptosis and Streptozotocin-Induced Diabetes Endocrinology, July 1, 2009; 150(7): 3031 - 3039. [Abstract] [Full Text] [PDF]

				J.-H. Lee, M.-Y. Song, E.-K. Song, E.-K. Kim, W. S. Moon, M.-K. Han, J.-W. Park, K.-B. Kwon, and B.-H. Park Overexpression of SIRT1 Protects Pancreatic {beta}-Cells Against Cytokine Toxicity by Suppressing the Nuclear Factor-{kappa}B Signaling Pathway Diabetes, February 1, 2009; 58(2): 344 - 351. [Abstract] [Full Text] [PDF]

				X.-J. Zhao, Q. Dong, J. Bindas, J. D. Piganelli, A. Magill, J. Reiser, and J. K. Kolls TRIF and IRF-3 Binding to the TNF Promoter Results in Macrophage TNF Dysregulation and Steatosis Induced by Chronic Ethanol J. Immunol., September 1, 2008; 181(5): 3049 - 3056. [Abstract] [Full Text] [PDF]

				M. Y. Donath, J. Storling, L. A. Berchtold, N. Billestrup, and T. Mandrup-Poulsen Cytokines and {beta}-Cell Biology: from Concept to Clinical Translation Endocr. Rev., May 1, 2008; 29(3): 334 - 350. [Abstract] [Full Text] [PDF]

				J. D. Rivas-Carrillo, A. Soto-Gutierrez, N. Navarro-Alvarez, H. Noguchi, T. Okitsu, Y. Chen, T. Yuasa, K. Tanaka, M. Narushima, A. Miki, et al. Cell-Permeable Pentapeptide V5 Inhibits Apoptosis and Enhances Insulin Secretion, Allowing Experimental Single-Donor Islet Transplantation in Mice Diabetes, May 1, 2007; 56(5): 1259 - 1267. [Abstract] [Full Text] [PDF]

				S. Kim, I. Millet, H. S. Kim, J. Y. Kim, M. S. Han, M.-K. Lee, K.-W. Kim, R. S. Sherwin, M. Karin, and M.-S. Lee NF-{kappa}B prevents beta cell death and autoimmune diabetes in NOD mice PNAS, February 6, 2007; 104(6): 1913 - 1918. [Abstract] [Full Text] [PDF]

				H. A. Arafat, A. K. Katakam, G. Chipitsyna, Q. Gong, A. R. Vancha, J. Gabbeta, and D. C. Dafoe Osteopontin Protects the Islets and {beta}-Cells from Interleukin-1 {beta}-Mediated Cytotoxicity through Negative Feedback Regulation of Nitric Oxide Endocrinology, February 1, 2007; 148(2): 575 - 584. [Abstract] [Full Text] [PDF]

				M. Montolio, M. Biarnes, N. Tellez, J. Escoriza, J. Soler, and E. Montanya Interleukin-1{beta} and inducible form of nitric oxide synthase expression in early syngeneic islet transplantation J. Endocrinol., January 1, 2007; 192(1): 169 - 177. [Abstract] [Full Text] [PDF]

				J.-C. Henquin, D. Dufrane, and M. Nenquin Nutrient Control of Insulin Secretion in Isolated Normal Human Islets Diabetes, December 1, 2006; 55(12): 3470 - 3477. [Abstract] [Full Text] [PDF]

				D. Liuwantara, M. Elliot, M. W. Smith, A. O. Yam, S. N. Walters, E. Marino, A. McShea, and S. T. Grey Nuclear Factor-{kappa}B Regulates {beta}-Cell Death: A Critical Role for A20 in {beta}-Cell Protection Diabetes, September 1, 2006; 55(9): 2491 - 2501. [Abstract] [Full Text] [PDF]

				F. Ortis, A. K. Cardozo, D. Crispim, J. Storling, T. Mandrup-Poulsen, and D. L. Eizirik Cytokine-Induced Proapoptotic Gene Expression in Insulin-Producing Cells Is Related to Rapid, Sustained, and Nonoscillatory Nuclear Factor-{kappa}B Activation Mol. Endocrinol., August 1, 2006; 20(8): 1867 - 1879. [Abstract] [Full Text] [PDF]

				A. S. Narang and R. I. Mahato Biological and biomaterial approaches for improved islet transplantation. Pharmacol. Rev., June 1, 2006; 58(2): 194 - 243. [Abstract] [Full Text] [PDF]

				R. Eldor, A. Yeffet, K. Baum, V. Doviner, D. Amar, Y. Ben-Neriah, G. Christofori, A. Peled, J. C. Carel, C. Boitard, et al. Conditional and specific NF-{kappa}B blockade protects pancreatic beta cells from diabetogenic agents PNAS, March 28, 2006; 103(13): 5072 - 5077. [Abstract] [Full Text] [PDF]

				M. Cnop, N. Welsh, J.-C. Jonas, A. Jorns, S. Lenzen, and D. L. Eizirik Mechanisms of Pancreatic {beta}-Cell Death in Type 1 and Type 2 Diabetes: Many Differences, Few Similarities Diabetes, December 1, 2005; 54(suppl_2): S97 - S107. [Abstract] [Full Text] [PDF]

				M. Y. Donath, J. A. Ehses, K. Maedler, D. M. Schumann, H. Ellingsgaard, E. Eppler, and M. Reinecke Mechanisms of {beta}-Cell Death in Type 2 Diabetes Diabetes, December 1, 2005; 54(suppl_2): S108 - S113. [Abstract] [Full Text] [PDF]

				S K Richards, L E Parton, I Leclerc, G A Rutter, and R M Smith Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo J. Endocrinol., November 1, 2005; 187(2): 225 - 235. [Abstract] [Full Text] [PDF]

				J. Rasschaert, L. Ladriere, M. Urbain, Z. Dogusan, B. Katabua, S. Sato, S. Akira, C. Gysemans, C. Mathieu, and D. L. Eizirik Toll-like Receptor 3 and STAT-1 Contribute to Double-stranded RNA+ Interferon-{gamma}-induced Apoptosis in Primary Pancreatic {beta}-Cells J. Biol. Chem., October 7, 2005; 280(40): 33984 - 33991. [Abstract] [Full Text] [PDF]

				J.-Y. Yang, J. Walicki, A. Abderrahmani, M. Cornu, G. Waeber, B. Thorens, and C. Widmann Expression of an Uncleavable N-terminal RasGAP Fragment in Insulin-secreting Cells Increases Their Resistance toward Apoptotic Stimuli without Affecting Their Glucose-induced Insulin Secretion J. Biol. Chem., September 23, 2005; 280(38): 32835 - 32842. [Abstract] [Full Text] [PDF]

				E. B. Hammar, J.-C. Irminger, K. Rickenbach, G. Parnaud, P. Ribaux, D. Bosco, D. G. Rouiller, and P. A. Halban Activation of NF-{kappa}B by Extracellular Matrix Is Involved in Spreading and Glucose-stimulated Insulin Secretion of Pancreatic Beta Cells J. Biol. Chem., August 26, 2005; 280(34): 30630 - 30637. [Abstract] [Full Text] [PDF]

				C. E. Mathews, W. L. Suarez-Pinzon, J. J. Baust, K. Strynadka, E. H. Leiter, and A. Rabinovitch Mechanisms Underlying Resistance of Pancreatic Islets from ALR/Lt Mice to Cytokine-Induced Destruction J. Immunol., July 15, 2005; 175(2): 1248 - 1256. [Abstract] [Full Text] [PDF]

				J. Storling, S. V. Zaitsev, I. L. Kapelioukh, A. E. Karlsen, N. Billestrup, P.-O. Berggren, and T. Mandrup-Poulsen Calcium Has a Permissive Role in Interleukin-1{beta}-Induced c-Jun N-Terminal Kinase Activation in Insulin-Secreting Cells Endocrinology, July 1, 2005; 146(7): 3026 - 3036. [Abstract] [Full Text] [PDF]

				H. Chen, X. Li, and P. N. Epstein MnSOD and Catalase Transgenes Demonstrate That Protection of Islets From Oxidative Stress Does Not Alter Cytokine Toxicity Diabetes, May 1, 2005; 54(5): 1437 - 1446. [Abstract] [Full Text] [PDF]

				H. Hui, N. Khoury, X. Zhao, L. Balkir, E. D'Amico, A. Bullotta, E. D. Nguyen, A. Gambotto, and R. Perfetti Adenovirus-Mediated XIAP Gene Transfer Reverses the Negative Effects of Immunosuppressive Drugs on Insulin Secretion and Cell Viability of Isolated Human Islets Diabetes, February 1, 2005; 54(2): 424 - 433. [Abstract] [Full Text] [PDF]

				A. K. Cardozo, F. Ortis, J. Storling, Y.-M. Feng, J. Rasschaert, M. Tonnesen, F. Van Eylen, T. Mandrup-Poulsen, A. Herchuelz, and D. L. Eizirik Cytokines Downregulate the Sarcoendoplasmic Reticulum Pump Ca2+ ATPase 2b and Deplete Endoplasmic Reticulum Ca2+, Leading to Induction of Endoplasmic Reticulum Stress in Pancreatic {beta}-Cells Diabetes, February 1, 2005; 54(2): 452 - 461. [Abstract] [Full Text] [PDF]

				T. Matsuda, K. Ferreri, I. Todorov, Y. Kuroda, C. V. Smith, F. Kandeel, and Y. Mullen Silymarin Protects Pancreatic {beta}-Cells against Cytokine-Mediated Toxicity: Implication of c-Jun NH2-Terminal Kinase and Janus Kinase/Signal Transducer and Activator of Transcription Pathways Endocrinology, January 1, 2005; 146(1): 175 - 185. [Abstract] [Full Text] [PDF]

				J.-Y. Yang, D. Michod, J. Walicki, B. M. Murphy, S. Kasibhatla, S. J. Martin, and C. Widmann Partial Cleavage of RasGAP by Caspases Is Required for Cell Survival in Mild Stress Conditions Mol. Cell. Biol., December 1, 2004; 24(23): 10425 - 10436. [Abstract] [Full Text] [PDF]

				P. Schott-Ohly, A. Lgssiar, H.-J. Partke, M. Hassan, N. Friesen, and H. Gleichmann Prevention of Spontaneous and Experimentally Induced Diabetes in Mice With Zinc Sulfate-Enriched Drinking Water Is Associated with Activation and Reduction of NF-{kappa}B and AP-1 in Islets, Respectively Experimental Biology and Medicine, December 1, 2004; 229(11): 1177 - 1185. [Abstract] [Full Text] [PDF]

				I. Kharroubi, L. Ladriere, A. K. Cardozo, Z. Dogusan, M. Cnop, and D. L. Eizirik Free Fatty Acids and Cytokines Induce Pancreatic {beta}-Cell Apoptosis by Different Mechanisms: Role of Nuclear Factor-{kappa}B and Endoplasmic Reticulum Stress Endocrinology, November 1, 2004; 145(11): 5087 - 5096. [Abstract] [Full Text] [PDF]

				E. Zeender, K. Maedler, D. Bosco, T. Berney, M. Y. Donath, and P. A. Halban Pioglitazone and Sodium Salicylate Protect Human {beta}-Cells against Apoptosis and Impaired Function Induced by Glucose and Interleukin-1{beta} J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5059 - 5066. [Abstract] [Full Text] [PDF]

				R. Bottino, A.N. Balamurugan, H. Tse, C. Thirunavukkarasu, X. Ge, J. Profozich, M. Milton, A. Ziegenfuss, M. Trucco, and J. D. Piganelli Response of Human Islets to Isolation Stress and the Effect of Antioxidant Treatment Diabetes, October 1, 2004; 53(10): 2559 - 2568. [Abstract] [Full Text] [PDF]

				B. Kutlu, A. K. Cardozo, M. I. Darville, M. Kruhoffer, N. Magnusson, T. Orntoft, and D. L. Eizirik Discovery of Gene Networks Regulating Cytokine-Induced Dysfunction and Apoptosis in Insulin-Producing INS-1 Cells Diabetes, November 1, 2003; 52(11): 2701 - 2719. [Abstract] [Full Text] [PDF]

				A. L. Scarim, S. Y. Nishimoto, S. M. Weber, and J. A. Corbett Role for c-Jun N-Terminal Kinase in {beta}-Cell Recovery from Nitric Oxide-Mediated Damage Endocrinology, August 1, 2003; 144(8): 3415 - 3422. [Abstract] [Full Text] [PDF]

				V. V. Tran, G. Chen, C. B. Newgard, and H. E. Hohmeier Discrete and Complementary Mechanisms of Protection of {beta}-Cells Against Cytokine-Induced and Oxidative Damage Achieved by bcl-2 Overexpression and a Cytokine Selection Strategy Diabetes, June 1, 2003; 52(6): 1423 - 1432. [Abstract] [Full Text] [PDF]

				I. Chang, S. Kim, J. Y. Kim, N. Cho, Y.-H. Kim, H. S. Kim, M.-K. Lee, K.-W. Kim, and M.-S. Lee Nuclear Factor {kappa}B Protects Pancreatic {beta}-Cells From Tumor Necrosis Factor-{alpha}-Mediated Apoptosis Diabetes, May 1, 2003; 52(5): 1169 - 1175. [Abstract] [Full Text] [PDF]

				K. K. Rehman, S. Bertera, R. Bottino, A. N. Balamurugan, J. C. Mai, Z. Mi, M. Trucco, and P. D. Robbins Protection of Islets by in Situ Peptide-mediated Transduction of the Ikappa B Kinase Inhibitor Nemo-binding Domain Peptide J. Biol. Chem., March 7, 2003; 278(11): 9862 - 9868. [Abstract] [Full Text] [PDF]

				A. K. Azevedo-Martins, S. Lortz, S. Lenzen, R. Curi, D. L. Eizirik, and M. Tiedge Improvement of the Mitochondrial Antioxidant Defense Status Prevents Cytokine-Induced Nuclear Factor-{kappa}B Activation in Insulin-Producing Cells Diabetes, January 1, 2003; 52(1): 93 - 101. [Abstract] [Full Text] [PDF]

				R. Riachy, B. Vandewalle, J. Kerr Conte, E. Moerman, P. Sacchetti, B. Lukowiak, V. Gmyr, T. Bouckenooghe, M. Dubois, and F. Pattou 1,25-Dihydroxyvitamin D3 Protects RINm5F and Human Islet Cells against Cytokine-Induced Apoptosis: Implication of the Antiapoptotic Protein A20 Endocrinology, December 1, 2002; 143(12): 4809 - 4819. [Abstract] [Full Text] [PDF]

				P. S. Kabouridis, M. Hasan, J. Newson, D. W. Gilroy, and T. Lawrence Inhibition of NF-{kappa}B Activity by a Membrane-Transducing Mutant of I{kappa}B{alpha} J. Immunol., September 1, 2002; 169(5): 2587 - 2593. [Abstract] [Full Text] [PDF]

				S. Cottet, P. Dupraz, F. Hamburger, W. Dolci, M. Jaquet, and B. Thorens cFLIP Protein Prevents Tumor Necrosis Factor-{alpha}-Mediated Induction of Caspase-8-Dependent Apoptosis in Insulin-Secreting {beta}Tc-Tet Cells Diabetes, June 1, 2002; 51(6): 1805 - 1814. [Abstract] [Full Text] [PDF]

				D. Zoukhri, R. R. Hodges, D. Byon, and C. L. Kublin Role of Proinflammatory Cytokines in the Impaired Lacrimation Associated with Autoimmune Xerophthalmia Invest. Ophthalmol. Vis. Sci., May 1, 2002; 43(5): 1429 - 1436. [Abstract] [Full Text] [PDF]

				D. Liu, A. K. Cardozo, M. I. Darville, and D. L. Eizirik Double-Stranded RNA Cooperates with Interferon-{gamma} and IL-1{beta} to Induce Both Chemokine Expression and Nuclear Factor-{kappa}B-Dependent Apoptosis in Pancreatic {beta}-Cells: Potential Mechanisms for Viral-Induced Insulitis and {beta}-Cell Death in Type 1 Diabetes Mellitus Endocrinology, April 1, 2002; 143(4): 1225 - 1234. [Abstract] [Full Text] [PDF]

				A. M. Alexander, M. Crawford, S. Bertera, W. A. Rudert, O. Takikawa, P. D. Robbins, and M. Trucco Indoleamine 2,3-Dioxygenase Expression in Transplanted NOD Islets Prolongs Graft Survival After Adoptive Transfer of Diabetogenic Splenocytes Diabetes, February 1, 2002; 51(2): 356 - 365. [Abstract] [Full Text] [PDF]

				H. Heimberg, Y. Heremans, C. Jobin, R. Leemans, A. K. Cardozo, M. Darville, and D. L. Eizirik Inhibition of Cytokine-Induced NF-{kappa}B Activation by Adenovirus-Mediated Expression of a NF-{kappa}B Super-Repressor Prevents {beta}-Cell Apoptosis Diabetes, October 1, 2001; 50(10): 2219 - 2224. [Abstract] [Full Text]

This Article Abstract Full Text (PDF) All Versions of this Article: 275/47/36509    most recent M005943200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giannoukakis, N. Articles by Robbins, P. D. Search for Related Content PubMed PubMed Citation Articles by Giannoukakis, N. Articles by Robbins, P. D. Social Bookmarking                      What's this?